Oral substitution treatment of injecting opioid users for prevention of HIV infection

Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R (2011)
The Cochrane database of systematic reviews (8): CD004145.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Gowing, Linda; Farrell, Michael F.; Bornemann, ReinhardUniBi; Sullivan, Lynn E.; Ali, Robert
Abstract / Bemerkung
Background Injecting drug users are vulnerable to infection with Human Immunodeficiency Virus (HIV) and other blood borne viruses as a result of collective use of injecting equipment as well as sexual behaviour Objectives To assess the effect of oral substitution treatment for opioid dependent injecting drug users on risk behaviours and rates of HIV infections\ Search strategy We searched the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE and PsycINFO toMay 2011. We also searched reference lists of articles, reviews and conference abstracts Selection criteria Studies were required to consider the incidence of risk behaviours, or the incidence of HIV infection related to substitution treatment of opioid dependence. All types of original studies were considered. Two authors independently assessed each study for inclusion Data collection and analysis Two authors independently extracted key information from each of the included studies. Any differences were resolved by discussion or by referral to a third author. Main results Thirty-eight studies, involving some 12,400 participants, were included. The majority were descriptive studies, or randomisation processes did not relate to the data extracted, and most studies were judged to be at high risk of bias. Studies consistently show that oral substitution treatment for opioid-dependent injecting drug users with methadone or buprenorphine is associated with statistically significant reductions in illicit opioid use, injecting use and sharing of injecting equipment. It is also associated with reductions in the proportion of injecting drug users reporting multiple sex partners or exchanges of sex for drugs or money, but has little effect on condom use. It appears that the reductions in risk behaviours related to drug use do translate into reductions in cases of HIV infection. However, because of the high risk of bias and variability in several aspects of the studies, combined totals were not calculated. Authors' conclusions Oral substitution treatment for injecting opioid users reduces drug-related behaviours with a high risk of HIV transmission, but has less effect on sex-related risk behaviours. The lack of data from randomised controlled studies limits the strength of the evidence presented in this review.
Humans; *rehabilitation]; Administration; Oral; Sexual Behavior; HIV Infections [*prevention &; control; transmission]; Opioid-Related Disorders [*rehabilitation]; Narcotics [*administration & dosage]; Intravenous [complications; Substance Abuse; Risk-Taking; as Topic; Randomized Controlled Trials
The Cochrane database of systematic reviews
Page URI


Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. The Cochrane database of systematic reviews. 2011;(8):CD004145.
Gowing, L., Farrell, M. F., Bornemann, R., Sullivan, L. E., & Ali, R. (2011). Oral substitution treatment of injecting opioid users for prevention of HIV infection. The Cochrane database of systematic reviews(8), CD004145. https://doi.org/10.1002/14651858.CD004145
Gowing, Linda, Farrell, Michael F., Bornemann, Reinhard, Sullivan, Lynn E., and Ali, Robert. 2011. “Oral substitution treatment of injecting opioid users for prevention of HIV infection”. The Cochrane database of systematic reviews, no. 8: CD004145.
Gowing, L., Farrell, M. F., Bornemann, R., Sullivan, L. E., and Ali, R. (2011). Oral substitution treatment of injecting opioid users for prevention of HIV infection. The Cochrane database of systematic reviews, CD004145.
Gowing, L., et al., 2011. Oral substitution treatment of injecting opioid users for prevention of HIV infection. The Cochrane database of systematic reviews, (8), p CD004145.
L. Gowing, et al., “Oral substitution treatment of injecting opioid users for prevention of HIV infection”, The Cochrane database of systematic reviews, 2011, pp. CD004145.
Gowing, L., Farrell, M.F., Bornemann, R., Sullivan, L.E., Ali, R.: Oral substitution treatment of injecting opioid users for prevention of HIV infection. The Cochrane database of systematic reviews. CD004145 (2011).
Gowing, Linda, Farrell, Michael F., Bornemann, Reinhard, Sullivan, Lynn E., and Ali, Robert. “Oral substitution treatment of injecting opioid users for prevention of HIV infection”. The Cochrane database of systematic reviews 8 (2011): CD004145.

42 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

An outbreak of HIV infection among people who inject drugs linked to injection of propofol in Taiwan.
Huang YC, Huang YF, Lin MH, Yang JY, Liao YH, Lo HY, Latkin C, Nelson KE., PLoS One 14(2), 2019
PMID: 30735511
Increasing diversion of methadone in Vancouver, Canada, 2005-2015.
Reddon H, Ho J, DeBeck K, Milloy MJ, Liu Y, Dong H, Ahamad K, Wood E, Kerr T, Hayashi K., J Subst Abuse Treat 85(), 2018
PMID: 29291766
Suboxone: Rationale, Science, Misconceptions.
Velander JR., Ochsner J 18(1), 2018
PMID: 29559865
Pharmacogenetics of Opioid Use Disorder Treatment.
Crist RC, Clarke TK, Berrettini WH., CNS Drugs 32(4), 2018
PMID: 29623639
Hepatitis C virus status awareness and test results confirmation among people who inject drugs in Ukraine.
Iakunchykova O, Meteliuk A, Zelenev A, Mazhnaya A, Tracy M, Altice FL., Int J Drug Policy 57(), 2018
PMID: 29655101
When is coercive methadone therapy justified?
D'Hotman D, Pugh J, Douglas T., Bioethics 32(7), 2018
PMID: 29883516
Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis.
Ma J, Bao YP, Wang RJ, Su MF, Liu MX, Li JQ, Degenhardt L, Farrell M, Blow FC, Ilgen M, Shi J, Lu L., Mol Psychiatry (), 2018
PMID: 29934549
Mobilizing community support in people receiving opioid-agonist treatment: A group approach.
Kidorf M, Brooner RK, Peirce J, Gandotra J, Leoutsakos JM., J Subst Abuse Treat 93(), 2018
PMID: 30126535
Barriers to access to opioid medicines for patients with opioid dependence: a review of legislation and regulations in eleven central and eastern European countries.
Vranken MJM, Mantel-Teeuwisse AK, Jünger S, Radbruch L, Scholten W, Lisman JA, Subataite M, Schutjens MDB., Addiction 112(6), 2017
PMID: 28087986
Primary Care Physicians' Willingness to Prescribe HIV Pre-exposure Prophylaxis for People who Inject Drugs.
Edelman EJ, Moore BA, Calabrese SK, Berkenblit G, Cunningham C, Patel V, Phillips K, Tetrault JM, Shah M, Fiellin DA, Blackstock O., AIDS Behav 21(4), 2017
PMID: 27896552
Design and implementation of a factorial randomized controlled trial of methadone maintenance therapy and an evidence-based behavioral intervention for incarcerated people living with HIV and opioid dependence in Malaysia.
Bazazi AR, Wickersham JA, Wegman MP, Culbert GJ, Pillai V, Shrestha R, Al-Darraji H, Copenhaver MM, Kamarulzaman A, Altice FL., Contemp Clin Trials 59(), 2017
PMID: 28479216
Malmö Treatment Referral and Intervention Study-High 12-Month Retention Rates in Patients Referred from Syringe Exchange to Methadone or Buprenorphine/Naloxone Treatment.
Bråbäck M, Ekström L, Troberg K, Nilsson S, Isendahl P, Brådvik L, Håkansson A., Front Psychiatry 8(), 2017
PMID: 28912734
Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs.
Platt L, Reed J, Minozzi S, Vickerman P, Hagan H, French C, Jordan A, Degenhardt L, Hope V, Hutchinson S, Maher L, Palmateer N, Taylor A, Hickman M., Cochrane Database Syst Rev 2016(1), 2016
PMID: 27127417
Harm reduction for young people who use prescription opioids extra-medically: Obstacles and opportunities.
Marshall BD, Green TC, Yedinak JL, Hadland SE., Int J Drug Policy 31(), 2016
PMID: 26919826
Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection.
Tetrault JM, Tate JP, Edelman EJ, Gordon AJ, Lo Re V, Lim JK, Rimland D, Goulet J, Crystal S, Gaither JR, Gibert CL, Rodriguez-Barradas MC, Fiellin LE, Bryant K, Justice AC, Fiellin DA., J Subst Abuse Treat 68(), 2016
PMID: 27431048
Pre-incarceration police harassment, drug addiction and HIV risk behaviours among prisoners in Kyrgyzstan and Azerbaijan: results from a nationally representative cross-sectional study.
Polonsky M, Azbel L, Wegman MP, Izenberg JM, Bachireddy C, Wickersham JA, Dvoriak S, Altice FL., J Int AIDS Soc 19(4 suppl 3), 2016
PMID: 27435715
High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011-14).
Wenz B, Nielsen S, Gassowski M, Santos-Hövener C, Cai W, Ross RS, Bock CT, Ratsch BA, Kücherer C, Bannert N, Bremer V, Hamouda O, Marcus U, Zimmermann R, DRUCK Study group., BMC Public Health 16(), 2016
PMID: 27595567
Combined prevention for persons who inject drugs in the HIV epidemic in a transitional country: the case of Tallinn, Estonia.
Uusküla A, Des Jarlais DC, Raag M, Pinkerton SD, Feelemyer J., AIDS Care 27(1), 2015
PMID: 25054646
Is the promise of methadone Kenya's solution to managing HIV and addiction? A mixed-method mathematical modelling and qualitative study.
Rhodes T, Guise A, Ndimbii J, Strathdee S, Ngugi E, Platt L, Kurth A, Cleland C, Vickerman P., BMJ Open 5(3), 2015
PMID: 25748417
Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV Prevention Trials Network 058.
Metzger DS, Donnell D, Celentano DD, Jackson JB, Shao Y, Aramrattana A, Wei L, Fu L, Ma J, Lucas GM, Chawarski M, Ruan Y, Richardson P, Shin K, Chen RY, Sugarman J, Dye BJ, Rose SM, Beauchamp G, Burns DN, HPTN 058 Protocol Team., J Acquir Immune Defic Syndr 68(5), 2015
PMID: 25564105
Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial.
D'Onofrio G, O'Connor PG, Pantalon MV, Chawarski MC, Busch SH, Owens PH, Bernstein SL, Fiellin DA., JAMA 313(16), 2015
PMID: 25919527
Increasing prevalence of HIV infection among first time clients in Italian drug treatment services - is it sexual transmission?
Cruciani M, Wiessing L, Serpelloni G, Genetti B, Andreotti A, Iulia C, Zermiani M, Suligoi B., BMC Infect Dis 15(), 2015
PMID: 25925747
Biomedical HIV Prevention Including Pre-exposure Prophylaxis and Opiate Agonist Therapy for Women Who Inject Drugs: State of Research and Future Directions.
Page K, Tsui J, Maher L, Choopanya K, Vanichseni S, Mock PA, Celum C, Martin M., J Acquir Immune Defic Syndr 69 Suppl 2(), 2015
PMID: 25978484
Non-Medical Prescription Opioid Use and Prescription Opioid Use Disorder: A Review.
Tetrault JM, Butner JL., Yale J Biol Med 88(3), 2015
PMID: 26339205
The impact of buprenorphine/naloxone treatment on HIV risk behaviors among HIV-infected, opioid-dependent patients.
Edelman EJ, Chantarat T, Caffrey S, Chaudhry A, O'Connor PG, Weiss L, Fiellin DA, Fiellin LE., Drug Alcohol Depend 139(), 2014
PMID: 24726429
Enhancing motivation within a rapid opioid substitution treatment feasibility RCT: a nested qualitative study.
Ayres R, Ingram J, Rees A, Neale J, Beattie A, Telfer M., Subst Abuse Treat Prev Policy 9(), 2014
PMID: 25407020
Mitigating the risk of HIV infection with opioid substitution treatment.
Gowing LR, Hickman M, Degenhardt L., Bull World Health Organ 91(2), 2013
PMID: 23554530
Managing psychiatric comorbidity within versus outside of methadone treatment settings: a randomized and controlled evaluation.
Brooner RK, Kidorf MS, King VL, Peirce J, Neufeld K, Stoller K, Kolodner K., Addiction 108(11), 2013
PMID: 23734943
Improving treatment enrollment and re-enrollment rates of syringe exchangers: 12-month outcomes.
Kidorf M, King VL, Gandotra N, Kolodner K, Brooner RK., Drug Alcohol Depend 124(1-2), 2012
PMID: 22209388
BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP.
Lingford-Hughes AR, Welch S, Peters L, Nutt DJ, British Association for Psychopharmacology, Expert Reviewers Group., J Psychopharmacol 26(7), 2012
PMID: 22628390
Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis.
MacArthur GJ, Minozzi S, Martin N, Vickerman P, Deren S, Bruneau J, Degenhardt L, Hickman M., BMJ 345(), 2012
PMID: 23038795

177 References

Daten bereitgestellt von Europe PubMed Central.

Retrospective analyses of additional services for methadone maintenance patients.
Abbott PJ, Moore B, Delaney H, Weller S., J Subst Abuse Treat 17(1-2), 1999
PMID: 10435261
Community reinforcement approach in the treatment of opiate addicts.
Abbott PJ, Weller SB, Delaney HD, Moore BA., Am J Drug Alcohol Abuse 24(1), 1998
PMID: 9513627
When is less treatment better? The role of social anxiety in matching methadone patients to psychosocial treatments.
Avants SK, Margolin A, Kosten TR, Rounsaville BJ, Schottenfeld RS., J Consult Clin Psychol 66(6), 1998
PMID: 9874905
Day treatment versus enhanced standard methadone services for opioid-dependent patients: a comparison of clinical efficacy and cost.
Avants SK, Margolin A, Sindelar JL, Rounsaville BJ, Schottenfeld R, Stine S, Cooney NL, Rosenheck RA, Li SH, Kosten TR., Am J Psychiatry 156(1), 1999
PMID: 9892294
Heroin use and HIV risk-taking behaviour among women injecting drug users
Baker, Drug and Alcohol Review 20(2), 2001
The privatisation of methadone maintenance; Changes in risk behavior associated with cost related detoxification
Britton, Addiction Research 2(2), 1994
Drug abuse treatment success among needle exchange participants.
Brooner R, Kidorf M, King V, Beilenson P, Svikis D, Vlahov D., Public Health Rep 113 Suppl 1(), 1998
PMID: 9722818
Gender, cocaine and during-treatment HIV risk reduction among injection opioid users in methadone maintenance.
Camacho LM, Bartholomew NG, Joe GW, Cloud MA, Simpson DD., Drug Alcohol Depend 41(1), 1996
PMID: 8793304
Maintenance of HIV risk reduction among injection opioid users: a 12 month posttreatment follow-up.
Camacho LM, Bartholomew NG, Joe GW, Simpson DD., Drug Alcohol Depend 47(1), 1997
PMID: 9279493
Gender differences at admission and follow-up in a sample of methadone maintenance clients.
Chatham LR, Hiller ML, Rowan-Szal GA, Joe GW, Simpson DD., Subst Use Misuse 34(8), 1999
PMID: 10359226
Predictors of positive outcomes for out-of-treatment opiate injectors recruited into methadone maintenance through street outreach
Corsi, Journal of Drug Issues 32(), 2002
A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system.
Dolan KA, Shearer J, MacDonald M, Mattick RP, Hall W, Wodak AD., Drug Alcohol Depend 72(1), 2003
PMID: 14563543
A low threshold methadone stabilisation programme - Description and first stage evaluation
Finch, Addiction Research 3(1), 1995
Reduction or cessation of injecting risk behaviours? Treatment outcomes at 1-year follow-up.
Gossop M, Marsden J, Stewart D, Kidd T., Addict Behav 28(4), 2003
PMID: 12726791
The National Treatment Outcome Research Study (NTORS): 4-5 year follow-up results.
Gossop M, Marsden J, Stewart D, Kidd T., Addiction 98(3), 2003
PMID: 12603229
HIV risk behaviors among women in methadone maintenance treatment.
Grella CE, Anglin D, Annon JJ., Subst Use Misuse 31(3), 1996
PMID: 8834263
What happens when a demonstration project ends. Consequences for a clinic and its clients.
Grella CE, Anglin MD, Rawson R, Crowley R, Hasson A., J Subst Abuse Treat 13(3), 1996
PMID: 9017568
Predictors of opiate drug abuse during a 90-day methadone detoxification.
Iguchi MY, Stitzer ML., Am J Drug Alcohol Abuse 17(3), 1991
PMID: 1928022
Influence of psychiatric comorbidity on HIV risk behaviors: changes during drug abuse treatment.
King VL, Kidorf MS, Stoller KB, Brooner RK., J Addict Dis 19(4), 2000
PMID: 11110066
Methadone maintenance as HIV risk reduction with street-recruited injecting drug users
Kwiatkowski, Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 26(5), 2001
Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS.
Lawrinson P, Ali R, Buavirat A, Chiamwongpaet S, Dvoryak S, Habrat B, Jie S, Mardiati R, Mokri A, Moskalewicz J, Newcombe D, Poznyak V, Subata E, Uchtenhagen A, Utami DS, Vial R, Zhao C., Addiction 103(9), 2008
PMID: 18636999
Outcomes of methadone maintenance 1 year after admission
Maddux, Journal of Drug Issues 27(2), 1997
Changes in cocaine use after entry to methadone treatment.
Magura S, Siddiqi Q, Freeman RC, Lipton DS., J Addict Dis 10(4), 1991
PMID: 1777498
A randomized clinical trial of a manual-guided risk reduction intervention for HIV-positive injection drug users.
Margolin A, Avants SK, Warburton LA, Hawkins KA, Shi J., Health Psychol 22(2), 2003
PMID: 12683743
Profiles of self-reported HIV-risk behaviors among injection drug users in methadone maintenance treatment, detoxification, and needle exchange programs.
Mark HD, Nanda J, Davis-Vogel A, Navaline H, Scotti R, Wickrema R, Metzger D, Sochalski J., Public Health Nurs 23(1), 2006
PMID: 16460416
Buprenorphine treatment for opioid dependence: the relative efficacy of daily, twice and thrice weekly dosing.
Marsch LA, Bickel WK, Badger GJ, Jacobs EA., Drug Alcohol Depend 77(2), 2005
PMID: 15664721
HIV infection and cocaine use in methadone maintained and untreated intravenous drug users.
Meandzija B, O'Connor PG, Fitzgerald B, Rounsaville BJ, Kosten TR., Drug Alcohol Depend 36(2), 1994
PMID: 7851277
Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up.
Metzger DS, Woody GE, McLellan AT, O'Brien CP, Druley P, Navaline H, DePhilippis D, Stolley P, Abrutyn E., J. Acquir. Immune Defic. Syndr. 6(9), 1993
PMID: 8340896
Reduction in injection-related HIV risk after 6 months in a low-threshold methadone treatment program.
Millson P, Challacombe L, Villeneuve PJ, Strike CJ, Fischer B, Myers T, Shore R, Hopkins S., AIDS Educ Prev 19(2), 2007
PMID: 17411415
HIV seroconversion in intravenous drug users in San Francisco, 1985-1990.
Moss AR, Vranizan K, Gorter R, Bacchetti P, Watters J, Osmond D., AIDS 8(2), 1994
PMID: 8043227
Feasibility of buprenorphine and methadone maintenance programmes among users of home made opioids in Ukraine.
Schaub M, Chtenguelov V, Subata E, Weiler G, Uchtenhagen A., Int. J. Drug Policy 21(3), 2009
PMID: 19926271
Feasibility of buprenorphine maintenance therapy programs in the Ukraine: first promising treatment outcomes.
Schaub M, Subata E, Chtenguelov V, Weiler G, Uchtenhagen A., Eur Addict Res 15(3), 2009
PMID: 19420948
Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial.
Sees KL, Delucchi KL, Masson C, Rosen A, Clark HW, Robillard H, Banys P, Hall SM., JAMA 283(10), 2000
PMID: 10714729
Methadone treatment as a determinant of HIV risk reduction among injecting drug users: a nested case-control study.
Serpelloni G, Carrieri MP, Rezza G, Morganti S, Gomma M, Binkin N., AIDS Care 6(2), 1994
PMID: 8061081
Client engagement and change during drug abuse treatment.
Simpson DD, Joe GW, Rowan-Szal G, Greener J., J Subst Abuse 7(1), 1995
PMID: 7655308
Methadone maintenance treatment and HIV risk-taking behaviour among injecting drug users in Berlin.
Stark K, Muller R, Bienzle U, Guggenmoos-Holzmann I., J Epidemiol Community Health 50(5), 1996
PMID: 8944860
Randomized trial of supervised injectable versus oral methadone maintenance: report of feasibility and 6-month outcome.
Strang J, Marsden J, Cummins M, Farrell M, Finch E, Gossop M, Stewart D, Welch S., Addiction 95(11), 2000
PMID: 11219367
Short-term Outcomes for the Treatment of Heroin Dependence: Findings From the Australian Treatment Outcome Study (ATOS)
Ross, Addictive Disorders and Their Treatment 5(3), 2006
One year outcomes for heroin dependence: findings from the Australian Treatment Outcome Study (ATOS).
Teesson M, Ross J, Darke S, Lynskey M, Ali R, Ritter A, Cooke R., Drug Alcohol Depend 83(2), 2005
PMID: 16343809
Methadone maintenance treatment and HIV type 1 seroconversion among injecting drug users.
Williams AB, McNelly EA, Williams AE, D'Aquila RT., AIDS Care 4(1), 1992
PMID: 1314099
Promoting abstinence from cocaine and heroin with a methadone dose increase and a novel contingency.
Epstein DH, Schmittner J, Umbricht A, Schroeder JR, Moolchan ET, Preston KL., Drug Alcohol Depend 101(1-2), 2008
PMID: 19101098
Hepatitis C and human immunodeficiency virus risk behaviors in polydrug users on methadone maintenance.
Willner-Reid J, Belendiuk KA, Epstein DH, Schmittner J, Preston KL., J Subst Abuse Treat 35(1), 2007
PMID: 17931826
Methadone maintenance and behavior by intravenous drug users that can transmit HIV
Abdul-Quader, Contemporary Drug Problems 14(), 1987
Longitudinal effects of LAAM and methadone maintenance on heroin addict behavior.
Anglin MD, Conner BT, Annon JJ, Longshore D., J Behav Health Serv Res 36(2), 2008
PMID: 19023658
Risk Factors and predictors of human immunodeficiency virus infection among injection drug users.
Backmund M, Meyer K, Henkel C, Reimer J, Wachtler M, Schutz CG., Eur Addict Res 11(3), 2005
PMID: 15990431
The effectiveness of methadone maintenance treatment in reducing intravenous drug use and needle sharing among heroin addicts at risk for AIDS
Ball, NIDA Research Monograph 90(), 1988
Reducing the risk of AIDS through methadone maintenance treatment.
Ball JC, Lange WR, Myers CP, Friedman SR., J Health Soc Behav 29(3), 1988
PMID: 3241064

Ball, 1991
Patients successfully maintained with methadone escaped human immunodeficiency virus infection.
Barthwell A, Senay E, Marks R, White R., Arch. Gen. Psychiatry 46(10), 1989
PMID: 2802930
HIV-infected i.v. drug users in methadone treatment: outcome and psychological correlates--a preliminary report.
Batki SL, Sorensen JL, Gibson DR, Maude-Griffin P., NIDA Res. Monogr. 95(), 1989
PMID: 2641010
HIV prevention between drug users
Bornemann, 1996
Drug injection cessation among HIV-infected injecting drug users.
Bouhnik AD, Carrieri MP, Rey D, Spire B, Gastaut JA, Gallais H, Obadia Y; MANIF 2000 Study Group., Addict Behav 29(6), 2004
PMID: 15236822
HIV risk reduction in outpatient drug abuse treatment: individual and geographic differences.
Broome KM, Joe GW, Simpson DD., AIDS Educ Prev 11(4), 1999
PMID: 10494354
The early course of change in methadone maintenance.
Cacciola JS, Alterman AI, Rutherford MJ, McKay JR, McLellan AT., Addiction 93(1), 1998
PMID: 9624710
Methadone maintenance and the likelihood of risky needle-sharing.
Caplehorn JR, Ross MW., Int J Addict 30(6), 1995
PMID: 7657397
Risk factors for HIV-1 seroconversion among injection drug users: a case-control study.
Chitwood DD, Griffin DK, Comerford M, Page JB, Trapido EJ, Lai S, McCoy CB., Am J Public Health 85(11), 1995
PMID: 7485667
The effect of methadone maintenance on positive outcomes for opiate injection drug users.
Corsi KF, Lehman WK, Booth RE., J Subst Abuse Treat 37(2), 2009
PMID: 19150202
Incarceration and drug use patterns among a cohort of injection drug users.
DeBeck K, Kerr T, Li K, Milloy MJ, Montaner J, Wood E., Addiction 104(1), 2009
PMID: 19133890
Methadone maintenance treatment reduces heroin injection in New South Wales prisons.
Dolan KA, Wodak AD, Hall WD., Drug Alcohol Rev 17(2), 1998
PMID: 16203480
Methadone maintenance treatment: outcomes from the Otago methadone programme.
Dore GM, Walker JD, Paice JR, Clarkson S., N. Z. Med. J. 112(1100), 1999
PMID: 10678242
[Prevalence of infection by HIV and hepatitis C virus in a cohort of patients on methadone treatment].
Esteban J, Gimeno C, Aragones A, Barril J, Pellin Mde L., Med Clin (Barc) 120(20), 2003
PMID: 12797927
[Two-year follow-up of an opioid-user cohort treated with high-dose buprenorphine (Subutex)]
Fhima A, Henrion R, Lowenstein W, Charpak Y., Ann Med Interne (Paris) 152 Suppl 3(), 2001
PMID: 11435992
Changes in HIV/AIDS risk behaviours in drug users in St. Louis: Applications of random regression models
Gallagher, Journal of Drug Issues 27(2), 1997
Effects of buprenorphine on needle sharing, drug use and drug craving in men with combined heroin and cocaine dependence
Gastfriend, NIDA Research Monograph 132(), 1993
Antisocial personality disorder, HIV risk behavior and retention in methadone maintenance therapy.
Gill K, Nolimal D, Crowley TJ., Drug Alcohol Depend 30(3), 1992
PMID: 1396106
Antisocial personality disorder and HIV infection among intravenous drug abusers.
Brooner RK, Greenfield L, Schmidt CW, Bigelow GE., Am J Psychiatry 150(1), 1993
PMID: 8417580
Validity of intravenous drug abusers' self-reported changes in HIV high-risk drug use behaviors.
Greenfield L, Bigelow GE, Brooner RK., Drug Alcohol Depend 39(2), 1995
PMID: 8529537
Prevention of HIV between intravenous drug users
Grimm, 1992
Patterns of heroin, cocaine and speedballs injection among Bronx (USA) methadone maintenance patients: 1978-1988
Hartel, Addiction Research 3(4), 1996
HIV prevalence and risk behavior among injecting drug users who participate in "low-threshold" methadone programs in Amsterdam.
Hartgers C, van den Hoek A, Krijnen P, Coutinho RA., Am J Public Health 82(4), 1992
PMID: 1312311
Methadone maintenance in prison: evaluation of a pilot program in Puerto Rico.
Heimer R, Catania H, Newman RG, Zambrano J, Brunet A, Ortiz AM., Drug Alcohol Depend 83(2), 2005
PMID: 16332415
Participation in an outreach-based coupon distribution program for free methadone detoxification
Bux, Hospital and Community Psychiatry 44(11), 1993
Changes in HIV risk behavior among injecting drug users: the impact of 21 versus 90 days of methadone detoxification.
Iguchi MY, Bux DA Jr, Lidz V, French JF, Baxter RC, Platt JJ., AIDS 10(14), 1996
PMID: 8970693
Correlates of drug injection behaviors among methadone outpatients.
Kang SY, De Leon G., Am J Drug Alcohol Abuse 19(1), 1993
PMID: 8438826
Methadone maintenance and cessation of injecting drug use: results from the Amsterdam Cohort Study.
Langendam MW, van Brussel GH, Coutinho RA, van Ameijden EJ., Addiction 95(4), 2000
PMID: 10829334
Trends in HIV risk behaviour and methadone dosage among HIV-negative drug users: an ecological study.
Langendam MW, van Brussel GH, Coutinho RA, van Ameijden EJ., AIDS 14(12), 2000
PMID: 10985334
Methadone maintenance treatment modalities in relation to incidence of HIV: results of the Amsterdam cohort study.
Langendam MW, van Brussel GH, Coutinho RA, van Ameijden EJ., AIDS 13(13), 1999
PMID: 10509573
Sex, drugs, and HIV: does methadone maintenance reduce drug use and risky sexual behavior?
Lollis CM, Strothers HS, Chitwood DD, McGhee M., J Behav Med 23(6), 2000
PMID: 11199087
Methadone maintenance and needle/syringe sharing.
Longshore D, Hsieh S, Danila B, Anglin MD., Int J Addict 28(10), 1993
PMID: 8407026
Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trial.
Lucas GM, Chaudhry A, Hsu J, Woodson T, Lau B, Olsen Y, Keruly JC, Fiellin DA, Finkelstein R, Barditch-Crovo P, Cook K, Moore RD., Ann. Intern. Med. 152(11), 2010
PMID: 20513828
Sex, drugs and HIV counseling and testing: a prospective study of behavior-change among methadone-maintenance clients in New England.
MacGowan RJ, Brackbill RM, Rugg DL, Swanson NM, Weinstein B, Couchon A, Scibak J, Molde S, McLaughlin P, Barker T, Voigt R., AIDS 11(2), 1997
PMID: 9030371
Factors associated with client-reported HIV infection among clients entering methadone treatment
MacGowan, AIDS Education & Prevention 9(3), 1997
Changes in HIV risk behaviors among cocaine-using methadone patients.
Magura S, Rosenblum A, Rodriguez EM., J Addict Dis 17(4), 1998
PMID: 9848033
Behavioural change in injecting drug users: evaluation of an HIV/AIDS education programme.
Martin GS, Serpelloni G, Galvan U, Rizzetto A, Gomma M, Morgante S, Rezza G., AIDS Care 2(3), 1990
PMID: 2088523
Outcomes of a 21-day drug detoxification program: retention, transfer to further treatment, and HIV risk reduction.
McCusker J, Bigelow C, Luippold R, Zorn M, Lewis BF., Am J Drug Alcohol Abuse 21(1), 1995
PMID: 7762537
Binge drug use independently predicts HIV seroconversion among injection drug users: implications for public health strategies.
Miller CL, Kerr T, Frankish JC, Spittal PM, Li K, Schechter MT, Wood E., Subst Use Misuse 41(2), 2006
PMID: 16393742
Reduced infections with HIV and hepatitis A during a Swiss intravenous opiate maintenance program.
Naef MR, Bucher HC, Erb P, Gyr N, Bassetti S, Battegay M., J. Acquir. Immune Defic. Syndr. 21(4), 1999
PMID: 10428117
[HIV prevention in HIV-positive drug addicts. A methadone-supported model]
Oertle D, Edelmann R, Ostewalder J, Vernazza PL, Galeazzi RL., Schweiz Med Wochenschr 123(48), 1993
PMID: 8272803
Risk dimensions of HIV-tested substance users.
Ottomanelli G., Int J Addict 28(14), 1993
PMID: 8307661
Effectiveness of first eight methadone maintenance treatment clinics in China.
Pang L, Hao Y, Mi G, Wang C, Luo W, Rou K, Li J, Wu Z., AIDS 21 Suppl 8(), 2007
PMID: 18172377
Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy.
Parran TV, Adelman CA, Merkin B, Pagano ME, Defranco R, Ionescu RA, Mace AG., Drug Alcohol Depend 106(1), 2009
PMID: 19717249
Impact of methadone on drug use and risky sex in China.
Qian HZ, Hao C, Ruan Y, Cassell HM, Chen K, Qin G, Yin L, Schumacher JE, Liang S, Shao Y., J Subst Abuse Treat 34(4), 2007
PMID: 17869049
Impact of drug maintenance treatment on injection practices among French HIV-infected IDUs. The MANIF 2000 Study Group.
Reynaud-Maurupt C, Carrieri MP, Gastaud JA, Pradier C, Obadia Y, Moatti JP., AIDS Care 12(4), 2000
PMID: 11091779
Retention, HIV risk, and illicit drug use during treatment: methadone dose and visit frequency.
Rhoades HM, Creson D, Elk R, Schmitz J, Grabowski J., Am J Public Health 88(1), 1998
PMID: 9584030
Buprenorphine in primary care: risk factors for treatment injection and implications for clinical management.
Roux P, Villes V, Blanche J, Bry D, Spire B, Feroni I, Carrieri MP., Drug Alcohol Depend 97(1-2), 2008
PMID: 18479840
A morphine prescription program in Italy (1980-1985): Retrospective evidence of protection against HIV/AIDS
Sagliocca, Addiction Research 5(2), 1997
Longitudinal changes in injection behaviors in a cohort of injection drug users.
Saxon AJ, Calsyn DA, Jackson TR., Addiction 89(2), 1994
PMID: 8173485
Risk factors for human immunodeficiency virus infection in intravenous drug users.
Schoenbaum EE, Hartel D, Selwyn PA, Klein RS, Davenny K, Rogers M, Feiner C, Friedland G., N. Engl. J. Med. 321(13), 1989
PMID: 2770823
A randomized controlled trial of interim methadone maintenance.
Schwartz RP, Highfield DA, Jaffe JH, Brady JV, Butler CB, Rouse CO, Callaman JM, O'Grady KE, Battjes RJ., Arch. Gen. Psychiatry 63(1), 2006
PMID: 16389204
Interim methadone treatment: impact on arrests.
Schwartz RP, Jaffe JH, O'Grady KE, Kinlock TW, Gordon MS, Kelly SM, Wilson ME, Ahmed A., Drug Alcohol Depend 103(3), 2009
PMID: 19443133
Impact of interim methadone maintenance on HIV risk behaviors.
Wilson ME, Schwartz RP, O'Grady KE, Jaffe JH., J Urban Health 87(4), 2010
PMID: 20386992
Knowledge about AIDS and high-risk behavior among intravenous drug users in New York City.
Selwyn PA, Feiner C, Cox CP, Lipshutz C, Cohen RL., AIDS 1(4), 1987
PMID: 3126773
Longitudinal predictors of injection cessation and subsequent relapse among a cohort of injection drug users in Baltimore, MD, 1988-2000.
Shah NG, Galai N, Celentano DD, Vlahov D, Strathdee SA., Drug Alcohol Depend 83(2), 2005
PMID: 16364568
Methadone maintenance and other factors associated with intraindividual temporal trends in injection-drug use.
Shore RE, Marmor M, Titus S, Des Jarlais DC., J Subst Abuse Treat 13(3), 1996
PMID: 9017567
HIV and hepatitis virus infections among injecting drug users in a medically controlled heroin prescription programme.
Steffen T, Blattler R, Gutzwiller F, Zwahlen M., Eur J Public Health 11(4), 2001
PMID: 11766485
Sex differences in risk factors for hiv seroconversion among injection drug users: a 10-year perspective.
Strathdee SA, Galai N, Safaiean M, Celentano DD, Vlahov D, Johnson L, Nelson KE., Arch. Intern. Med. 161(10), 2001
PMID: 11371255
A trial of integrated buprenorphine/naloxone and HIV clinical care.
Sullivan LE, Barry D, Moore BA, Chawarski MC, Tetrault JM, Pantalon MV, O'Connor PG, Schottenfeld RS, Fiellin DA., Clin. Infect. Dis. 43 Suppl 4(), 2006
PMID: 17109305
Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence.
Fiellin DA, Pantalon MV, Chawarski MC, Moore BA, Sullivan LE, O'Connor PG, Schottenfeld RS., N. Engl. J. Med. 355(4), 2006
PMID: 16870915
Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors.
Sullivan LE, Moore BA, Chawarski MC, Pantalon MV, Barry D, O'Connor PG, Schottenfeld RS, Fiellin DA., J Subst Abuse Treat 35(1), 2007
PMID: 17933486
Factors associated with incarceration and incident human immunodeficiency virus (HIV) infection among injection drug users participating in an HIV vaccine trial in Bangkok, Thailand, 1999-2003.
Suntharasamai P, Martin M, Vanichseni S, van Griensven F, Mock PA, Pitisuttithum P, Tappero JW, Sangkum U, Kitayaporn D, Gurwith M, Choopanya K; Bangkok Vaccine Evaluation Group, Choopanya K, Vanichseni S, Prasittipol B, Srisuwanvilai LO, Subhachaturas W, Sangkum U, Bussaratid V, Kaewkungwal J, Kitayaporn D, Migasena S, Phonrat B, Pitisuttithum P, Pungpak S, Suntharasamai P, Chaowanachan T, Cherdtrakulkiat T, Kittikraisak W, Leelawiwat W, Martin M, McNicholl J, Na-Pompet S, Sinthuwattanawibul C, Tappero JW, van Griensven F, Wasinrapee P, Young N, Hu D, Mastro TD, Berman P, Brooks LB, Chernow M, Francis D, Gee C, Gurwith M, Heyward W, Ippolito T, Jobes D, Kalanon T, Li E, Luck A, Orelind K, Orozco-Cronin P, Peterson ML, Sinangil F, Metch B, Wang M, Hudgens M., Addiction 104(2), 2009
PMID: 19149819
AIDS in Italy.
Tidone L, Sileo F, Goglio A, Borra GC., Am J Drug Alcohol Abuse 13(4), 1987
PMID: 3687903
[Medical and psychosocial effects of methadone substitution in HIV infected substance-dependent patients]
Walger P, Baumgart P, Wilke G, Kupfer U, von Eiff M, Dorst KG., Psychother Psychosom Med Psychol 39(11), 1989
PMID: 2587688
High-risk sexual behaviors of intravenous drug users in- and out-of-treatment: implications for the spread of HIV infection.
Watkins KE, Metzger D, Woody G, McLellan AT., Am J Drug Alcohol Abuse 18(4), 1992
PMID: 1449121
Changing needle practices in community outreach and methadone treatment
Wechsberg, Evaluation & Program Planning 17(4), 1994
Retention in methadone maintenance is associated with reductions in different HIV risk behaviors for women and men.
Wells EA, Calsyn DA, Clark LL, Saxon AJ, Jackson TR., Am J Drug Alcohol Abuse 22(4), 1996
PMID: 8911589
Injecting behaviour and risky needle use amongst methadone maintenance clients.
White JM, Dyer KR, Ali RL, Gaughwin MD, Cormack S., Drug Alcohol Depend 34(2), 1994
PMID: 8026298
Adherence to methadone is associated with a lower level of HIV-related risk behaviors in drug users.
Wong KH, Lee SS, Lim WL, Low HK., J Subst Abuse Treat 24(3), 2003
PMID: 12810144
HIV risk behavior in treatment-seeking opioid-dependent youth: results from a NIDA clinical trials network multisite study.
Meade CS, Weiss RD, Fitzmaurice GM, Poole SA, Subramaniam GA, Patkar AA, Connery HS, Woody GE., J. Acquir. Immune Defic. Syndr. 55(1), 2010
PMID: 20393347
Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial.
Woody GE, Poole SA, Subramaniam G, Dugosh K, Bogenschutz M, Abbott P, Patkar A, Publicker M, McCain K, Potter JS, Forman R, Vetter V, McNicholas L, Blaine J, Lynch KG, Fudala P., JAMA 300(17), 2008
PMID: 18984887
Influence of a methadone maintenance programme on the improved outcome of a cohort on injecting drug users with advanced HIV disease.
Antela A, Casado JL, Gonzalez MJ, Perez P, Perez-Elias MJ, Montilla P, Buzon L., AIDS 11(11), 1997
PMID: 9302458
Needle sharing
Bornemann, 1998

Higgins, 0
Self-report among injecting drug users: a review.
Darke S., Drug Alcohol Depend 51(3), 1998
PMID: 9787998
HIV infection among intravenous drug users: Epidemiology and emerging public health perspectives
Jarlais, 1992
Methadone maintenance at different dosages for opioid dependence.
Faggiano F, Vigna-Taglianti F, Versino E, Lemma P., Cochrane Database Syst Rev (3), 2003
PMID: 12917925
Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.
Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, Collins J, Raisch D, Casadonte P, Goldsmith RJ, Ling W, Malkerneker U, McNicholas L, Renner J, Stine S, Tusel D; Buprenorphine/Naloxone Collaborative Study Group., N. Engl. J. Med. 349(10), 2003
PMID: 12954743
Syringe-mediated drug sharing among injecting drug users: patterns, social context and implications for transmission of blood-borne pathogens.
Grund JP, Friedman SR, Stern LS, Jose B, Neaigus A, Curtis R, Des Jarlais DC., Soc Sci Med 42(5), 1996
PMID: 8685737
Epidemiology of HIV infection
Kaldor, 1994
Modelling infectious diseases and other health consequences: Predicting further morbidity consequences and spread of HIV, Hepatitis B and Hepatitis C
Kretzschmar, 2001
Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review.
Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, Wodak A, Panda S, Tyndall M, Toufik A, Mattick RP; 2007 Reference Group to the UN on HIV and Injecting Drug Use, Azim T, Guarinieri M, Hickman M, Kamarulzaman A, Malinowska-Sempruch K, Mesquita F, Mokri A, Onigbogi OO, Owiti F, Panda S, Strathdee S, Sulliman F, Toufik A, Toufiq J, Tyndall M, Wiessing L., Lancet 372(9651), 2008
PMID: 18817968
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.
Mattick RP, Kimber J, Breen C, Davoli M., Cochrane Database Syst Rev (2), 2008
PMID: 18425880
Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.
Mattick RP, Breen C, Kimber J, Davoli M., Cochrane Database Syst Rev (3), 2009
PMID: 19588333
The virus and the tests
Mortimer, 2001
Medical care for injection-drug users with human immunodeficiency virus infection.
O'Connor PG, Selwyn PA, Schottenfeld RS., N. Engl. J. Med. 331(7), 1994
PMID: 8035842
The epidemiology of acquired immunodeficiency syndrome
Rutherford, 1989
Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST).
Spire B, Lucas GM, Carrieri MP., Int. J. Drug Policy 18(4), 2007
PMID: 17689374

The use of methadone during maintenance treatment: pharmacology, dosage and treatment outcome
Ward, 1998




Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

PMID: 21833948
PubMed | Europe PMC

Suchen in

Google Scholar